

SUNSI Review
Complete
Template = ADM-013
E-RIDS=ADM-03
ADD: Jennifer A. Davis

As of: 1/10/20 10:39 AM
Received: January 09, 2020
Status: Pending_Post
Tracking No. 1k4-9ecf-2a9e
Comments Due: January 13, 2020
Submission Type: Web

PUBLIC SUBMISSION

COMMENT (1)
PUBLICATION DATE:
11/27/2019
CITATION 84 FR
65424

Docket: NRC-2019-0173
SHINE Medical Technologies, LLC

Comment On: NRC-2019-0173-0003
SHINE Medical Technologies, LLC

Document: NRC-2019-0173-DRAFT-0001
Comment on FR Doc # 2019-25788

Submitter Information

Name: Kenneth Westlake

Address:

77 W. Jackson Blvd. (RM-19J)
U.S. Environmental Protection Agency
Chicago, IL, 60604

Email: westlake.kenneth@epa.gov

General Comment

A copy of this comment letter will be emailed to Jennifer Davis.

Attachments

EPA Comments - SHINE NOI for SFEIS 1-9-2020



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
REGION 5
77 WEST JACKSON BOULEVARD
CHICAGO, IL 60604-3590

JAN 09 2020

REPLY TO THE ATTENTION OF:

RM-19J

Jennifer Davis
Nuclear Regulatory Commission
Office of Administration
Mail Stop TWFN-7-A60M
Washington, DC 20555-0001

Re: Notice of Intent to Prepare a Supplement to the Final Environmental Impact Statement for the Construction Permit Related to the Operating License Application for the SHINE Medical Isotope Production Facility, Janesville, Rock County, Wisconsin

Dear Ms. Davis:


The U.S. Environmental Protection Agency has reviewed the referenced Nuclear Regulatory Commission (NRC) Notice of Intent (NOI), dated November 27, 2019 to prepare a supplement to the Final Environmental Impact Statement (FEIS). Our review is pursuant to our authorities under the National Environmental Policy Act (NEPA), Council on Environmental Quality regulations (40 CFR Parts 1500-1508), and Section 309 of the Clean Air Act.

SHINE Medical Technologies, LLC (the applicant) proposes to operate a facility in Janesville, Wisconsin, now under construction, for the production of molybdenum-99 through the irradiation and processing of a uranyl sulfate solution. The facility would include an irradiation facility and radioisotope production facility. Issuance of the and operating license would authorize the applicant to operate the SHINE Medical Isotope Production Facility for a 30-year period.

EPA provided comments on this proposed project for scoping, dated August 14, 2013, for the Draft Environmental Impact Statement (DEIS), dated July 2, 2015, and for the FEIS, dated November 30, 2015. We have no comments on the NOI. We look forward to reviewing any new information presented in the forthcoming supplement to the FEIS.

EPA is available to discuss the contents of this letter at your convenience. Please feel free to contact Mike Sedlacek of my staff at 312-886-1765 or at sedlacek.michael@epa.gov.

Sincerely,

A handwritten signature in black ink, appearing to read "Kenneth A. Westlake", written over a horizontal line.

Kenneth A. Westlake
Deputy Director, Tribal and Multimedia Programs Office
Office of the Regional Administrator